Detail akcie CASI Rg online

Business Summary: CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Company’s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Company’s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, CASI Pharmaceuticals Inc revenues decreased 11% to $13.5M. Net loss increased 41% to $35M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Change in fair value of investment in eq decrease from $2.9M (income) to $179K (expense), General and administrative increase of 14% to $18.7M (expense).